An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.
Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-.
Works about clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterized as RANDOMIZED CONTROLLED TRIALS AS TOPIC.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.

Thrombolytic therapy in Europe: current status. (1/39)

Thrombolytic therapy is a practical, effective approach to the management of acute myocardial infarction that is widely used in Europe today. Early European trials demonstrated a clear reduction in mortality in patients who received thrombolytic therapy compared with those given conventional treatment. The findings of experimental studies suggest that early reperfusion of the infarct-related artery reduces myocardial damage, which results in the preservation of left ventricular function and, in turn, may improve survival. Although tissue plasminogen activator (t-PA) has been shown to produce more rapid and complete reperfusion than streptokinase, two large-scale clinical trials in which t-PA was given as a standard 3- or 4-h infusion provided no evidence of a survival advantage with this agent. However, the accelerated t-PA regimen used in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study was associated with a lower mortality than streptokinase or a combination of t-PA and streptokinase, thus lending support to the 'open artery' theory. Two recent studies conducted in Europe, the Grampian Region Early Anistreplase Trial (GREAT) and the European Myocardial Infarction Project (EMIP), have demonstrated the feasibility, safety, and efficacy of early thrombolytic therapy before admission to hospital. In GREAT, anistreplase (APSAC) was administered at home by general practitioners. In EMIP, this same agent was given by emergency medical personnel. In both studies, pre-hospital administration reduced the time between the onset of symptoms and initiation of thrombolysis and was associated with a lower mortality rate. Recent data from the European Cooperative Group Study show that the benefits of thrombolytic therapy are maintained for up to 5 years. Research continues in an effort to develop safer and more effective thrombolytic agents. Educational efforts to familiarize the public with the symptoms of myocardial infarction and the development of more rapid, efficient emergency response systems may also improve the outcome of thrombolytic therapy by shortening the time between symptom onset and thrombolytic drug administration.  (+info)

Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. (2/39)

OBJECTIVE: To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction. DESIGN: Patients were randomly allocated to receive either 1.5 x 10(6) IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and subsequently at intervals up to 30 months; plasma samples were assayed for streptokinase resistance titre (functional assay) and streptokinase binding by IgG (microradioimmunoassay). SETTING: Cardiology department in a general hospital. PATIENTS: 128 consecutive eligible patients. Samples were collected for up to one year according to a prospective design: a subsection of 47 patients was selected for intensive study over the first 14 days. After one year, all available patients (67) were sampled on one further occasion. RESULTS: Antibody responses to streptokinase and anistreplase were similar. Streptokinase resistance titres exceeded pretreatment concentrations five days after dosing, and values peaked at 14 days. By 12 months after dosing, 92% of resistance titres (n = 84) had returned to within the pretreatment range. Antistreptokinase IgG concentrations also exceeded baseline concentrations within five days and peaked at 14 days. Half of the individual values had returned to within the pretreatment range by 12 months (n = 84) and 89% by 30 months (n = 18). CONCLUSION: Although we cannot be sure of the clinical significance, because of the increased likelihood of resistance due to antistreptokinase antibody, streptokinase and anistreplase may not be effective if administered more than five days after an earlier dose of streptokinase or anistreplase, particularly between five days and 12 months, and increased antistreptokinase antibody may increase the risk of allergic-type reactions.  (+info)

Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. (3/39)

OBJECTIVE: To assess the feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners. DESIGN: Randomised double blind parallel group trial of anistreplase 30 units intravenously and placebo given either at home or in hospital. SETTING: 29 rural practices in Grampian admitting patients to teaching hospitals in Aberdeen (average distance 36 (range 16-62) miles). PATIENTS: 311 patients with suspected acute myocardial infarction and no contraindications to thrombolytic therapy seen at home within four hours of onset of symptoms. MAIN OUTCOME MEASURES: Time saving, adverse events, Q wave infarction, left ventricular function. RESULTS: Anistreplase was administered at home 101 minutes after onset of symptoms, while anistreplase was given in hospital 240 minutes after onset of symptoms (median times). Adverse events after thrombolysis were infrequent and, apart from cardiac arrest, not a serious problem when they occurred in the community: seven of 13 patients were resuscitated after cardiac arrest out of hospital. By three months after trial entry the relative reduction of deaths from all causes in patients given thrombolytic therapy at home was 49% (13/163 (8.0%) v 23/148 (15.5%); difference -7.6% (95% confidence interval -14.7% to -0.4%), p = 0.04). Full thickness Q wave infarction was less common in patients with confirmed infarction receiving treatment at home (65/122 (53.3%) v 76/112 (67.9%); difference -14.6% (95% confidence interval -27.0% to -2.2%), p = 0.02). CONCLUSIONS: General practitioners provided rapid pre-hospital coronary care of a high standard. Compared with later administration in hospital, giving anistreplase at home resulted in reduction in mortality, fewer cardiac arrests, fewer Q wave infarcts, and better left ventricular function. Benefits were most marked where thrombolytic therapy was administered within two hours of the onset of symptoms.  (+info)

Oesophageal dissection after thrombolytic treatment for myocardial infarction. (4/39)

A 62 year old woman admitted with a history suggesting acute myocardial infarction had thrombolytic treatment with anisoylated plasminogen-streptokinase activator complex, which resulted in submucosal haemorrhage in the oesophagus; this caused dissection of the wall of the oesophagus and complete dysphagia. The haematoma resolved spontaneously, leaving behind a diverticulum, with reduced peristalsis and delayed emptying but no obstruction.  (+info)

The pharmacological modulation of thrombin-induced cerebral thromboembolism in the rabbit. (5/39)

1. Intracarotid (i.c.) administration of thrombin induced a marked accumulation of 111indium-labelled platelets and 125I-labelled fibrinogen within the cranial vasculature of anaesthetized rabbits. 2. Thrombin (100 iu kg-1, i.c.) - induced platelet accumulation was completely abolished by pretreatment with desulphatohirudin (CGP 39393; 1 mg kg-1 i.c., 1 min prior to thrombin). Administration of CGP 39393 1 or 20 min after thrombin produced a significant reduction in platelet accumulation. 3. Intravenous (i.v.) administration of the platelet activating factor (PAF) receptor antagonist BN 52021 (10 mg kg-1) 5 min prior to thrombin (100 iu kg-1, i.c.) had no effect on platelet accumulation. 4. An inhibitor of NO biosynthesis, L-NG-nitro arginine methyl ester (L-NAME; 100 mg kg-1, i.c.), had no significant effect on the cranial platelet accumulation response to thrombin (10 iu kg-1, i.c.) when administered 5 min prior to thrombin. 5. Defibrotide (32 or 64 mg kg-1 bolus i.c. followed by 32 or 64 mg kg-1 h-1, i.c., infusion for 45 min) treatment begun 20 min after thrombin (100 iu kg-1, i.c.) did not significantly modify the cranial platelet accumulation response. 6. Cranial platelet accumulation induced by thrombin (100 iu kg-1, i.c.) was significantly reversed by the fibrinolytic drugs urokinase (20 iu kg-1, i.c., infusion for 45 min), anisoylated plasminogen streptokinase activator complex (APSAC) (200 micrograms kg-1, i.v. bolus) or recombinant tissue plasminogen activator (rt-PA; 100 micrograms kg-1, i.c. bolus followed by 20 micrograms kg-1 min-1, i.c., infusion for 45 min) administered 20 min after thrombin.8. These results suggest that neither endogenous PAF nor NO modulate thrombin-induced intracranial platelet accumulation in the rabbit. However, fibrin deposition appears to play an important role as shown by the ability of fibrinolytic agents to reverse platelet and fibrinogen accumulation induced by i.c. thrombin.  (+info)

Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. (6/39)

PURPOSE: Over the past 2 decades the use of thrombolytic therapy in the management of peripheral occlusive diseases, most notably peripheral arterial occlusion (PAO) and deep venous thrombosis (DVT), has become an accepted and potentially preferable alternative to surgery. We examined the period when urokinase was in short supply and subsequently unavailable, to explore potential differences in clinical outcome and economic effect between urokinase and recombinant tissue plasminogen activator (rt-PA). MATERIAL AND METHODS: Data were obtained from the Premier Perspective Database, a broad clinical database that contains information on inpatient medical practices and resource use. The study population included all patients hospitalized in 1999 and 2000 with a primary or secondary diagnosis of PAO or DVT. Incidence was calculated for common adverse events, including bleeding complications, intracranial hemorrhage, amputation, and death. Cost data were also abstracted from the database, and are expressed as mean +/- SD. RESULTS: Demographic variables were similar in the urokinase and rt-PA groups. The rate of bleeding complications was similar in the urokinase and rt-PA groups. There were no intracranial hemorrhages in the urokinase group, compared with a rate of 1.5% in the rt-PA PAO group (P = .087) and 1.9% in the rt-PA DVT group (P = .175). The in-hospital mortality rate was lower in the urokinase-treated PAO subgroup (3.6% vs 8.5%; P = .026), but a similar finding in the DVT subgroup did not achieve statistical significance (4% vs 9.8%; P = .069). While pharmacy costs were greater in the urokinase-treated group (US 5472 dollars +/- US 5579 dollars vs US 3644 dollars +/- US 6009 dollars, P < .001; PAO subgroup, US 11,070 dollars +/- US 15,409 dollars vs US 6150 dollars +/- US 12,398 dollars, P = .003), overall hospital costs did not differ significantly between the 2 groups. This finding appears to be explained by a shorter hospital stay and reduced room and board costs in the urokinase-treated group. CONCLUSION: There were significant differences in outcome in patients with PAO and DVT who received treatment with urokinase and rt-PA. While pharmacy costs were significantly greater when urokinase was used, reduction in length of stay accounted for similar total hospital costs compared with rt-PA. These findings must be considered in the context of the retrospective nature of the analysis and the potential to use dosing regimens that differ from those in this study.  (+info)

Serum myoglobin and creatine kinase enzymes in acute myocardial infarction treated with Anistreplase. (7/39)

AIMS: To compare plasma myoglobin concentration and cardiac enzyme activity with electrocardiographic (ECG) changes in two groups of patients (reperfused and non-reperfused) participating in a placebo-controlled randomised double blind trial of treatment of myocardial infarction (MI) with intravenous thrombolytic therapy (Anistreplase). METHODS: Twenty two patients with confirmed MI obeying strict inclusion and exclusion criteria were studied. Plasma myoglobin was measured by radioimmunoassay and creatine kinase enzyme (CK and CKMB) by NAC activated and NAC activated/immunoinhibition methods respectively in all patients before and at frequent intervals after injection of Anistreplase or placebo. Patients were divided into reperfused (R) and non-reperfused (NR) groups on the basis of ECG criteria. Reperfusion was diagnosed if the measured ST segment elevation fell by greater than or equal to 50% at 2 hours post dosing. RESULTS: The time to peak (TTP) myoglobin was significantly less in the R group compared with the NR group but there was considerable overlap in the range of values. The area under the enzyme time curves (AUCs) and summed ST segment epsilon ST elevations were significantly smaller in the R compared with the NR group. CONCLUSIONS: Although TTP myoglobin results were significantly lower in the R group, TTP myoglobin will probably not be useful as an non-invasive indicator of reperfusion because of the overlap in values between the two groups. The significant reduction in the AUC and epsilon ST only in the R group suggests decreased infarct size. However, in this small preliminary study reperfusion did not occur more frequently with Anistreplase than without.  (+info)

Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. (8/39)

The thrombolytic and systemic effects of BM 06.022 were evaluated and compared with those of alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. BM 06.022 consists of the kringle-2 and protease domains of human tissue plasminogen activator (t-PA) and is unglycosylated because of its expression in Escherichia coli cells. Thrombus formation in anesthetized open chest dogs was induced by electrical injury to the intimal surface of the left circumflex coronary artery at a high level site of obstruction. In heparinized dogs, none of six vehicle-treated animals exhibited reperfusion. Reperfusion was achieved in four of six dogs at 18.3 +/- 6 min after intravenous bolus injection of 140 kU/kg (0.24 mg/kg) of BM 06.022, whereas four of six dogs exhibited reperfusion later (p less than 0.05) at 76.5 +/- 16.1 min during infusion of 1.33 mg/kg of alteplase (0.13 mg/kg as initial bolus injection, followed by 0.66 mg/kg over 1 h and 0.53 mg/kg over 2 h). Significantly later (p less than 0.05) reperfusion than that achieved with BM 06.022 was achieved in five of six dogs at 57.8 +/- 12.1 min after intravenous injection of 0.4 U/kg of anistreplase. Streptokinase (21,000 IU/kg over 60 min) and urokinase (20,000 IU/kg as an intravenous bolus injection, followed by 20,000 IU/kg over 89 min) each induced reperfusion in three of six dogs but at 67 +/- 12 and 84.3 +/- 17.1 min (p less than 0.05 vs. BM 06.022), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)  (+info)

TY - JOUR. T1 - Drug eruptions and isotypic antibody responses to streptokinase after infusions of anisoylated plasminogen-streptokinase complex (APSAC, anistreplase). AU - Dykewicz, Mark S.. AU - McMorrow, Nora K Y. AU - Davison, Richard. AU - Fintel, Dan J.. AU - Zull, Caryn Cochran. AU - Rutledge, Joyce L.. PY - 1995/1/1. Y1 - 1995/1/1. N2 - Background: Anisoylated plasminogen-streptokinase complex (APSAC, anistreplase) is a thrombolytic agent (131 kd) used for treatment of myocardial infarction. Like its principal antigenic determinant, streptokinase, APSAC has been reported to cause a variety of allergic reactions. Objectives: This study was intended to determine any association between isotypic antibody responses to streptokinase and observed allergic reactions to APSAC. Methods: We measured sequential IgM, IgG, IgA, and IgE antistreptokinase serum levels in 21 patients who received APSAC or tissue-type plasminogen activator in a prospective, double-blind study. Results: Of 11 patients who ...
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction Academic Article ...
One measure of the success of thrombolysis is the early patency status of the infarct-related coronary artery. The Thrombolysis in Myocardial Infarction (TIMI) study group designated patency grades 0 (occluded) or 1 (minimal perfusion) as thrombolysis failure and grade 2 (partial perfusion) or 3 (complete perfusion) as success. To evaluate their true functional significance, perfusion grades were compared with enzymatic and electrocardiographic (ECG) indexes of myocardial infarction in 359 patients treated within 4 h with anistreplase (APSAC) or streptokinase. Serum enzymes and ECGs were assessed serially. Patency was determined at 90 to 240 min (median 2.1 h) and graded by an observer who had no knowledge of patient data.. Results for the two drug arms were similar and combined. Distribution of patency was grade 0 = 20%, n = 72; grade 1 = 8%, n = 27; grade 2 = 16%, n = 58 and grade 3 = 56%, n = 202. Interventions were performed after angiography but within 24 h in 51% (n = 37), 70% (n = 19), ...
The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction. The DDD of urokinase is based on treatment of acute lung emboli. The DDDs are either expressed in international units or gram ...
An initiative of Alzheimers Australia, this website is a practical and comprehensive resource to help people to plan ahead for their future. It gives the information needed to make decisions and helps to put decisions into action. Resources include worksheets to help people step through the processes involved in planning ahead. It also has information and up to date links for all States and Territories as well as information available in 30 languages.. ...
All trials randomized patients to fibrinoltyic therapy or control. Treatment for each trial was as follows: GISSI-1: streptokinase (SK), 1.5 MU vs open control ISAM: SK, 1.5 MU vs placebo; single IV bolus aspirin; IV heparin, 5000 U + 800-1000 U/h for 72-96 h AIMS: APSAC, 30 U vs placebo; IV heparin at 6 h, 1000-1500 U/h ISIS-2: SK, 1.5 MU vs placebo; aspirin ASSET: tPA, 100 mg vs placebo; IV heparin, 5000 U + 1000 U/h for 24 h USIM: urokinase, 1 MU x 2 bolus vs open control; IV heparin, 10000 U + 1000 U/h for 48 h ISIS-3: SK, 1.5 MU or tPA, 0.6 MU/kg or APSAC, 30 U vs open control; aspirin; SC heparin, 12500 U bd for 7 days EMERAS: SK, 1.5 MU vs placebo; aspirin LATE: tPA, 100 mg vs placebo; aspirin; IV heparin, 5000 U + 1000 U/h for 48 h. ...
Westhill Academy, Grampian Region: A Report by HM Inspectors of Schools by Great Britain, 9780748048748, available at Book Depository with free delivery worldwide.
There is a need for a simple clinical measurement that will indicate the extent of myocardial salvage after successful thrombolysis. This study examined whether coronary artery reperfusion reduced the infarct size as assessed electrocardiographically after thrombolytic treatment. The sum of the (sigma) ST segment area in leads showing ST segment elevation in the 12 lead electrocardiogram at presentation was used as an index of potential myocardial injury (initial ischaemic index). The evolved infarct size at 48 h was assessed by a QRS scoring system. Two groups of patients, both admitted with anterior myocardial infarction within 6 h of onset, were studied. Group 1 (n = 35) received analgesia only and group 2 (n = 33) received thrombolytic treatment either by the intracoronary (streptokinase, n = 13) or intravenous route (anistreplase, n = 20). Reperfusion was assessed angiographically. The mean (SD) potential infarct size assessed by the initial ischaemic index was similar in both groups (group ...
The patient was started on effective product treatment 18 months prior precedent to this episode and pa had experienced progressive difficulty with swallowing since was then. The difficulty conferred with swallowing returned again sent after I finished stitching the second round trip of Norvasc, and my doctors have nt prescribed conditions it again. Although the Pentosan polysulfate sodium in napratec is next included to reduce at the risk calculus of Anistreplase side effects on the gut, these entity types of side eff
Grampians Tourism: TripAdvisor has 27,600 reviews of Grampians Hotels, Attractions, and Restaurants making it your best Grampians resource.
Ballarat Health provides a range of community and bed-based mental health services for children and young people (0 - 18 years) , adults (16 - 64 years), and older persons (over the age of 65) affected by serious complex mental illness across western Victorian (Grampians Region). Programs delivered cover the Local Government Areas of Hindmarsh, West Wimmera, Horsham, Yarriambiack, Northern Grampians, Ararat, Hepburn, Pyrenees, Ballarat, Moorabool and Golden Plains (part).
This half day workshop will deliver an interactive workshop for PCAs working in community and aged care. The workshop is designed to enhance your skills and develop a better understanding about Symptom Management and a Palliative Approach for older people living in residential aged care or the community.. ...
Victoria, West Victoria, Grampians. Located 260 kms west of Melbourne, the Grampians have a lot to offer the traveller. Spectacular rock formations, mountains and scenery make it a popular getaway. For the 4wder, there are numerous 4wd tracks to explore.
Eventbrite - ACK presents PAMIS Family Fun Day - Grampian - Saturday, 15 July 2017 at Aberdeen Sports Village - Sports Centre, Aberdeen, Scotland. Find event and ticket information.
Each link below will provide you with recycling information for the Northern Grampians Shire Council area. Using any of these services can help reduce the amount of waste going to landfill and ensure you place the right thing in the right bin.. ...
Child maltreatment has different definitions across the nation but generally involves harm to a child or a child being placed at risk of harm by a caregiver. When a reporter notifies CPS of an allegation, they will begin a process to collect information and ultimately reach a finding about whether or not maltreatment occurred. During the course of the investigation, CPS may or may not choose to litigate the case for various reasons. A psychological evaluation could be requested to address questions about if a child was harmed, and about whether or not the child was placed at a significant risk for harm. Psychologists have several tools, including a well-established research base, to provide valid and reliable opinions in this area.. Dr. Maddux has conducted several 100 evaluations in the area of child maltreatment. He is a member of the largest professional society for child maltreatment professionals in the nation (APSAC) and he sits on its Board of Directors. He has supervised other ...
Disclaimer: ANY-Web Ltd. cannot be held responsible for any problems or losses encountered as a result of your use of its sites. Please read our Full Disclaimer and Privacy Statement for more details. Your use of our sites is bound by their terms ...
now 3 landscapes until The Red Series Kicks Off! 39; Outstanding colonial Winter community asking heart - The Red Series. wondering sales from the Pyrenees and Grampians documents frequently under the one court, compatibility prices, a area nature supporting a particular landscape site, only with large new information, will peer.
In 2005 Chest Heart & Stroke Scotland (CHSS), in partnership with NHS Grampian, identified the need for specialist training for nurses and other health professionals working with stroke patients and their families.. With the appointment of a stroke education facilitator, NHS Grampian has been successfully providing education, training courses and study days throughout the region.. The courses have been designed as:. ...
Professor Lovell held high positions in the American Society for Testing and Materials (ASTM), the American Society of Civil Engineers (ASCE), the Transportation Research Board, and other professional organizations, from which he received numerous awards. He was a Fellow of both the ASTM and the ASCE. He was a past district governor of Lions International, a past president of the Lafayette Lions Club, a member of the Board of Directors of the Lafayette Rotary Club, a past president of the Greater Lafayette Civic Theatre, a charter member of the Covenant Presbyterian Church, West Lafayette, and an elder of the Central Presbyterian Church, Lafayette ...
Ballarat & Grampians Private Practice (B&GPP) is a business unit of Ballarat Health Services. The B&GPP provides space for medical specialists to operate their own private practice within Ballarat Health Services.
Tinelli, Michela, Scotland, Graham and Watson, Margaret (2009) An economic evaluation of the NHS Grampian Opportunistic Chlamydia Screening Study. . University of Aberdeen, Aberdeen, UK. ...
Every effort has been made to acknowledge the original authors of any external images used. But on the most part images and content in this blog are copyrighted to Margaret Lawson (c) 2013. All rights reserved ...
Common areas. As is expected of such a long-established, community based facility you will feel as though you are entering a calm and welcoming home-like environment. Residents are provided with large, open lounge areas, comfortably furnished with individual recliner chairs and couches, and large TV (LCD) screens for ease of viewing, or may escape into quieter sitting rooms. Fresh, daily-made meals are served in the large open dining areas or alternatively there is access to a private dining room for residents and family, designed to make you feel relaxed and at home.. Sweeping gardens with uninterrupted views to the Grampians provide space to stroll and relax within private and secure outdoor areas that incorporate courtyards, established trees, manicured gardens and raised garden beds, and peaceful retreats maintained by community volunteers. All of this and yet only a short walk into the centre of town, where an array of shops and local businesses boast services for your convenience.. In ...
Thrombolytic drugs are widely used for the management of cerebral venous sinus thrombosis patients. Several in vitro models have been developed to study clot lytic activity of thrombolytic drugs, but all of these have certain limitations. There is need of an appropriate model to check the clot lytic efficacy of thrombolytic drugs. In the present study, an attempt has been made to design and develop a new model system to study clot lysis in a simplified and easy way using a thrombolytic drug, streptokinase. Whole blood from healthy individuals (n = 20) was allowed to form clots in a pre-weighed sterile microcentrifuge tubes; serum was removed and clot was weighed. After lysis by streptokinase fluid was removed and remnants of clot were again weighed along with the tube. Percentage of Clot lysis was calculated on the basis of the weight difference of microcentrifuge tubes obtained before and after clot lysis. There was a significant percentage of clot lysis observed when streptokinase was used. On the
In GREAT, median call-to-needle times were 55 and 185 minutes for prehospital and hospital groups; 90% and 1% of measurements were ⩽ 90 minutes, respectively.1 In this audit, comprising many of the same practices that took part in the trial, the corresponding times were improved, at 45 minutes for prehospital thrombolysis, and 145 minutes for hospital thrombolysis. The improvement is most marked for the hospital group, where call-to-needle times were 40 minutes shorter in the audit than in the trial. This was largely owing to shortening of door-to-needle times in hospital, from 87 minutes in GREAT (estimated mean), to 35 minutes (median) in this audit.. Call-to-opiate times give an indication of the first opportunity for thrombolysis, which may be initiated about 15 minutes after opiate is given. In both prehospital and hospital groups, median call-to-opiate times were about half an hour.. In some rural areas of Scotland, thrombolytic treatment is given by general practitioners in community ...
Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, (765) 494-4600. © 2015 Purdue University , An equal access/equal opportunity university , Copyright Complaints , Maintained by Office of XYZ. Trouble with this page? Disability-related accessibility issue? Please contact Office of XYZ at [email protected] ...
Learn about how technology can help you gain greater independence and make day to day tasks easier. Our Access Technology specialist will be covering a variety of topics and you can join as many sessions as you like. Topics and Dates Using an iPhone with vision loss - tips, tricks, settings and apps Tuesday, 17 November from 11:00am to 12:00pm. What is a Google home and why is it so useful for someone with vision loss? Tuesday, 24 November from 11:00am to 12:00pm.
Attribution: © Aberdeenshire Archaeological Service. You may: copy, display, store and make derivative works [eg documents] solely for licensed personal use at home or solely for licensed educational institution use by staff and students on a secure intranet.. Under these conditions: Display Attribution, No Commercial Use or Sale, No Public Distribution [eg by hand, email, web]. Full Terms & Conditions and Licence details. ...
All data on NatureShare is licensed under a Creative Commons Attribution 2.5 Australia License . Free: NatureShare is, and will always be, a free and open service. Warranty: NatureShare services and all software are provided on an as is basis without warranties of any kind, either express or implied, including, without limitation, fitness for a particular purpose. Your use of the services is at your sole risk. We do not guarantee the accuracy or timeliness of information available from the service. Copyright: NatureShare software is copyright Reilly Beacom (2014) (Australia) ...
Common areas. As is expected of such a long-established, community based facility you will feel as though you are entering a calm and welcoming home-like environment. Residents are provided with large, open lounge areas, comfortably furnished with individual recliner chairs and couches, and large TV (LCD) screens for ease of viewing, or may escape into quieter sitting rooms. Fresh, daily-made meals are served in the large open dining areas or alternatively there is a private dining room for residents and family, designed to make you feel relaxed and at home.. Sweeping gardens with uninterrupted views to the Grampians provide space to stroll and relax within private and secure outdoor areas that incorporate courtyards, established trees, manicured gardens and raised garden beds, and peaceful retreats maintained by community volunteers. All of this and yet only a short walk into the centre of town, where an array of shops and local businesses boast services for your convenience.. In addition to ...
Following the recent success of the smoking cessation sessions at RGU, we followed up with the two advisors from NHS Grampian who ran the sessions. As a whole the sessions were a great success. Two people followed the journey through to the quitting stage, which is really exciting, well done to them! Other people managed…
This paper forms the second part of the debate on prehospital thrombolysis (PHT). It is argued that large scale studies have failed to show a benefit for PHT, even when the time saved over conventional treatment was considerably greater than would be the case in the UK urban setting. In practice, a relatively small proportion of the total population receiving thrombolysis would receive PHT. Other strategies to reduce time to thrombolysis can benefit all patients and are likely to be more cost effective and safer.. ...
An audit of the 12 acute health services in the Grampians region was conducted in January 2016 to determine the regions preparedness for CPE and guide the development of resources to fill the gaps.. A CPE Resource Kit was developed. This kit consisted of a CPE policy template, Emergency Department Infectious Disease Quick Reference Guide that included triage triggers to identify CPE, an Infection Prevention and Control Screening Tool for all emergency department presentations and admissions, an Extra Precautions Information Booklet for Patients, a staff information sheet and power point presentation to raise awareness of CPE detection and management. The kit was released in February 2016.. ...
Streptokinase (SK) is a bacterial protein used clinically as a thrombolytic agent in humans. Administration of SK causes a rapid increase in the frequency of anti-SK T cells and the titre of specific anti-SK antibodies that, on subsequent administration of SK, may neutralize the activity of the drug or elicit allergic-type reactions. By locating and modifying the immunogenic T-cell epitopes within the SK protein, it is possible that an agent with reduced immunogenicity but equal efficacy may be produced. We have investigated the T-cell epitopes within SK using nine non-overlapping, recombinant peptide fragments of SK. We investigated the proliferative T-cell response of peripheral blood mononuclear cells obtained from patients before and 6 days after administration of SK for myocardial infarction. We also examined the response of cultured anti-SK T-cell lines derived from patients 6 days after treatment with SK. Before administration of SK, peripheral blood mononuclear cells from six of nine ...
Councils Aged & Disability Services aim to provide comprehensive and co-ordinated support services for the frail aged and people with a disability from all cultural backgrounds, and their carers.
Lambs!. Eastertime is here and the egg rolling done happened and the shiny guy got nailed already! Me, I was up in the Grampian hills around New Pitsligo checking out those magnificent Recumbent Stone Circles. Ive now been to 87 of them and theres at least 15 more on my list I just gots to see. If the next shamanic generation is really on its way, then I reckon Grampian is gonna be the place for the main axis of the scene. Its cheap, far away and the temples are already in place. All we gotta do is crawl up there. And these places are so overlooked that I found loads of Neolithic tools still wedged between a Recumbent stone and its flanker at one temple - beautiful sparkling things that must have lain there for millennia. I gotta go back there because theres more just waiting, so dont expect me to clue you in to what circle it was. Hey, and I even took a photo of St. Kanes church in New Deer. Kane? Saint Kane? Are we talking reluctant Christianity here or what?. Lambs! Running around the ...
What number of various positions have you possessed the capacity to incorporate? Its sensors convey through Bluetooth with an application for iOS cell phones. The recorded therapeutic information that remaining parts mysterious however can be shared not exclusively to perform with companions at the same time, ideally, to impart profitable data to your specialist for instance. An extremely shrewd condom, so, for a similarly savvy utilize, we trust.. Numerous men after spinal string damage encounter changes in their sexual capacity (and enthusiastic issues can be added to them that further influence sexuality). It is critical that the man and his partner are educated about the idea of the issues and the chances to confront them. You also need to know Is urethral insertion safe?. Male sexual capacity Regularly the male presents two sorts of erection, the psychogenic and the reflex. Psychogenic erection is controlled by the mind, because of visual, sound-related or mental upgrades. The flag from the ...
DALLAS - The use of thrombolytics before angioplasty or stenting offers no benefit and appears to increase the risk of heart attacks, strokes, or death.
Now complete, Bennetts Associates Suttie Centre aims to forge links between medical teaching and clinical practice. The £21m project is a partnership between the University of Aberdeen and NHS Grampian housing state-of-the-art teaching and learning
Do you want to stop smoking but dont know where to start? Over the coming months, in conjunction with NHS Grampian, we will be offering Smoking Cessation advice, group sessions and drop in opportunities for all students and staff on campus. Promotional material will be available in the next couple of weeks, with sessions starting in…
A new study into the treatment of gallbladder stones, which lead to around 80,000 operations a year, is being directed by NHS Grampian and the University of Aberdeen.
7. Mike Rumbles (North East Scotland) (LD) To ask the Scottish Government what the impact has been on NHS Grampians patient service record of the figures from the Scottish Parliament information centre, which suggest that the boards NRAC funding targets have not been met since 2009, leading to a £165.6 million discrepancy. (S5O-01550). The Cabinet Secretary for Health and Sport (Shona Robison) As I explained last week, NHS Grampian was 3.7 per cent behind its target funding allocation when the NHS Scotland resource allocation committee formula was introduced in 2009-10. That is a position that we inherited. The Scottish Government has invested significantly in supporting the boards that are behind parity and, since 2015-16, NHS Grampian has received additional funding of £47 million for the specific purpose of accelerating the achievement of NRAC parity.. We expect all health boards, including NHS Grampian, to meet and maintain national performance targets and standards from the resources ...
The Mobile Library Service visits the Southern Grampians towns of Balmoral, Cavendish, Coleraine, Dunkeld, Glenthompson, Mirranatwa and Penshurst. Visit this page for the mobile library timetable.
We live on 280 acres, with 1 of 2 sons & small dog, nestled under the highest peaks of the Grampians National Park, 20 kms south of Halls Gap. We operate the Grampians Paradise Camping & Caravan Parkland, a beautiful, small camping ground with shady trees, gardens, small lake & wetlands. Native birds, animals & frogs abound. Bright starry skies. Work with us on environmental projects, fencing, gardening, maintenance, personal vegie garden and fruit orchard, firewood collection, ground works, jobs about the camping ground, occasional building projects (Aidan is very into Traditonal Timber Framing and nearly always has a project on the go). Caravan accom for 1-2 people with own cooking facilities and the use of the camp kitchen and amenities in the camping ground. Require own bedding. Campground amenities building has bathrooms and laundry. No children. Some independent cooking and possibly some shared meals with family. Prefer No Smoking, and No Smoking Indoors under any circumstance. Can pick up ...
Thrombolytic drugs or clot-busters are used to dissolve blood clots that are blocking blood flow to the heart. When given soon after a heart attack begins, these drugs can limit or prevent permanent damage to the heart. To he most effective, these drugs need to be administered within one hour from the commencement of the attack. ...
Set in the Royal Deeside town of Banchory, less than 15 miles from Aberdeen, Bancon Homes new Lochside of Leys development is situated in one of Aberdeenshires most stunning and sought-after locations.. Offering modern living at its very best, Banchory combines a secluded woodland setting with fantastic amenities close by. The town, steeped in local history, is spoilt for choice when it comes to local attractions and outdoor activities, as well as a range of town services and eateries.. Favoured by Queen Victoria, who is said to have fallen in love with the area, Banchory offers an idyllic lifestyle, surrounded by impressive natural landscape. Woodland walks, wildlife and the great outdoors are all key parts of Banchorys beauty.. Beautiful scenery. From Lochside of Leys you can walk to the summit of Scolty Hill, taking in the panoramic views over Royal Deeside and the Grampian mountains. And just a short walk from Banchorys town centre lies the Falls of Feugh, where visitors can explore the ...
Youll surely love the tranquil settings and spectacular scenery at the picturesque waterfalls located within the Grampians National Park.
Two special forums will be held in Ararat and Horsham. Thanks to a generous contribution from RACV, and local support from Grampians Integrated Cancer Service, these forums will be free.
By ROSALIND GRIFFITHS A MAN who had a lung removed by surgeons in Aberdeen after a mistaken cancer diagnosis is claiming compensation from NHS Grampian. Former firefighter Laurie Ball, 58, from Mossbank, was told shortly after the operation that he did not have cancer, but he said that he has had neither an
... is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a ... Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction. Early treatment gives better ... Anistreplase is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the ... Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377-381. doi:10.1136/jech.47.5.377. ...
Anistreplase Desmoteplase Streptokinase Nattokinase Lumbrokinase Serrapeptase Papain DNase Bromelain Honokiol Dugdale, David et ...
More recently, drugs such as tissue plasminogen activator, urokinase, and anistreplase have been used in their place. ...
... anistreplase) This disambiguation page lists articles associated with the title APSAC. If an internal link led you here, you ...
... anistreplase MeSH D12.776.124.125.662.537.900 - streptodornase and streptokinase MeSH D12.776.124.125.662.768 - tissue ...
... anistreplase (INN) anitrazafen (INN) anivamersen (USAN, INN) Anodynos-DHC Anolor 300 Anoquan anpirtoline (INN) anrukinzumab ( ...
... anistreplase) Engerix-B (hepatitis B vaccine) Floxapen (flucloxacillin) granisetron Havrix (hepatitis A vaccine) Orbenin ( ...
... anistreplase MeSH D08.811.277.656.300.775.900 - streptodornase and streptokinase MeSH D08.811.277.656.350 - exopeptidases MeSH ... anistreplase MeSH D08.811.277.656.300.760.640 - proprotein convertase 1 MeSH D08.811.277.656.300.760.646 - proprotein ...
Tenecteplase Anistreplase (Eminase) In people who receive thrombolytic therapy delivered through a catheter, there is a risk of ...
... and anistreplase to each other, and also compared the anticoagulant heparin to no heparin. All patients were also given aspirin ... a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin ...
... combinations with proton pump inhibitors B01AD01 Streptokinase B01AD02 Alteplase B01AD03 Anistreplase B01AD04 Urokinase B01AD05 ...
Read more about the prescription drug ANISTREPLASE - INJECTION. ... anistreplase-injection, Eminase. The display and use of drug ... Consumer information about the medication ANISTREPLASE - INJECTION (Eminase), includes side effects, drug interactions, ... GENERIC NAME: ANISTREPLASE - INJECTION (an-ISS-treh-plays). BRAND NAME(S): Eminase. Medication Uses , How To Use , Side Effects ...
Like anistreplase, it can affect your entire body.. *Tenecteplase: This works efficiently and is a frequent choice of many ... Anistreplase: Because this targets all plasminogen, not just the ones attached to fibrin, it can work throughout your whole ...
APSAC (anistreplase) is a complex of streptokinase and plasminogen that does not require free circulating plasminogen to be ... Like streptokinase, anistreplase does not distinguish between fibrin-bound and circulating plasminogen; consequently, it too ... The adult dose of APSAC (anistreplase) for AMI is 30 U given IV over 2-5 minutes. ...
APSAC (anistreplase) is a complex of streptokinase and plasminogen that does not require free circulating plasminogen to be ... Like streptokinase, anistreplase does not distinguish between fibrin-bound and circulating plasminogen; consequently, it too ... The adult dose of APSAC (anistreplase) for AMI is 30 U given IV over 2-5 minutes. ...
108010058207 Anistreplase Proteins 0.000 claims description 6 * 206010051055 Deep vein thrombosis Diseases 0.000 claims ...
... five-year results of the Grampian Region Early Anistreplase Trial (GREAT). Journal of the American College of Cardiology 1997; ...
The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute ...
ANISTREPLASE 56365 BOTULISM TOXIN 56370 CALCIUM CITRATE 56375 CARBOPLATIN 56380 CARTEOLOL 56390 CEFPROZIL 56395 CISAPRIDE 56415 ...
plasminogen activators (Alteplase/Reteplase/Tenecteplase, Streptokinase, Urokinase/Saruplase, Anistreplase) • other serine ...
Anistreplase - Concept préféré Concept UI. M0024829. Terme préféré. Anistreplase Synonymes. APSAC Complexe activateur ...
Anistreplase (substance). Code System Preferred Concept Name. Anistreplase (substance). Concept Status. Published. ...
APSAC (anistreplase) is a complex of streptokinase and plasminogen that does not require free circulating plasminogen to be ... Like streptokinase, anistreplase does not distinguish between fibrin-bound and circulating plasminogen; consequently, it too ... The adult dose of APSAC (anistreplase) for AMI is 30 U given IV over 2-5 minutes. ...
alteplase (tpa) • anistreplase • streptokinase • urokinase . Results indicated that there are two successive first-order ... anistreplase • streptokinase • urokinase basicities and sulfated versus non-sulfated • streptokinase urokinase! Costly than ...
Nouns with 12 letters. Full list of words with these elements: relationship, organisation, introduction, unemployment, organization, construction, distribution...
Dowling, R. J. O., Sparano, J. A., Goodwin, P. J., Bidard, F. C., Cescon, D. W., Chandarlapaty, S., Deasy, J. O., Dowsett, M., Gray, R. J., Henry, N. L., Meric-Bernstam, F., Perlmutter, J., Sledge, G. W., Thorat, M. A., Bratman, S. V., Carey, L. A., Chang, M. C., DeMichele, A., Ennis, M., Jerzak, K. J., & 12 othersKorde, L. A., Lohmann, A. E., Mamounas, E. P., Parulekar, W. R., Regan, M. M., Schramek, D., Stambolic, V., Whelan, T. J., Wolff, A. C., Woodgett, J. R., Kalinsky, K. & Hayes, D. F., Dec 1 2019, In: JNCI Cancer Spectrum. 3, 4, pkz049.. Research output: Contribution to journal › Review article › peer-review ...
Ans.Anistreplase. 10.All of the following are adverse effects of Bromocriptine except. Ans. Infertility and Ammenorrhoea. 11. ... 9.Which of the following will convert plasminogen to plasminAns.Anistreplase. 10.Leucovorin related sm MCQAns. option B. in ...
Anistreplase (Eminase) consists of streptokinase in a noncovalent 1:1 complex with plasminogen. Anistreplase is catalytically ... Anistreplase is more effective than streptokinase in establishing coronary reperfusion, but it causes considerable ...
anistreplase. *Immune Thrombocytopenia. *Qualitative Platelet Disorders. *Gastrointestinal Bleeding. *Acute Coronary Syndromes ...
You can purchase a small effect for anistreplase. Since they the meaning into doubt and to do with the title of this short ...
Streptokinase and Anistreplase: incidence of hypotension of 7%. *TPA: incidence of hypotension of 4% ...
... anistreplase (Eminase), dipyridamole (Persantine), streptokinase (Kabikinase, Streptase), ticlopidine (Ticlid), and urokinase ( ...
AnistreplaseEliquisTinzaparinApixabanInnohepDextranSavaysaPradaxaDabigatranEdoxaban. Reviewed by ...
Sk and anistreplase induce the opposite way, decreasing the probability of colorectal of its actions indirectly by releasing ...
Anistreplase [D08.811.277.656.300.775.075] * Streptodornase and Streptokinase [D08.811.277.656.300.775.900] ...
Find information on Streptokinase (Kabbikinase, Streptase) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
Find information on Ticlopidine (Ticlid) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
In the early 1920s, there was an outbreak of a previously unrecognized cattle disease in the northern United States and Canada. Cattle were haemorrhaging after minor procedures and on some occasions, spontaneously.[82] For example, 21 out of 22 cows died after dehorning and 12 out of 25 bulls died after castration. All of these animals had bled to death.[83]. In 1921, Frank Schofield, a Canadian veterinary pathologist, determined that the cattle were ingesting moldy silage made from sweet clover, and that this was functioning as a potent anticoagulant.[82] Only spoiled hay made from sweet clover (grown in northern states of the USA and in Canada since the turn of the century) produced the disease.[84] Schofield separated good clover stalks and damaged clover stalks from the same hay mow, and fed each to a different rabbit. The rabbit that had ingested the good stalks remained well, but the rabbit that had ingested the damaged stalks died from a haemorrhagic illness. A duplicate experiment with a ...
Anistreplase , Criança , Feminino , Humanos , Recém-Nascido , Mães/psicologia , Síndrome de Munchausen Causada por Terceiro/ ...
  • The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction. (whocc.no)